Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Zagar, Timothy M., James R. Oleson, Zeljko Vujaskovic, Mark W. Dewhirst, Oana I. Craciunescu, Kimberly L. Blackwell, Leonard R. Prosnitz, and Ellen L. Jones. “Hyperthermia for locally advanced breast cancer..” Int J Hyperthermia 26, no. 7 (2010): 618–24. https://doi.org/10.3109/02656736.2010.501051.

PMID
20849257
Full Text

Vujaskovic, Zeljko, Dong W. Kim, Ellen Jones, Lan Lan, Linda McCall, Mark W. Dewhirst, Oana Craciunescu, et al. “A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer..” Int J Hyperthermia 26, no. 5 (2010): 514–21. https://doi.org/10.3109/02656731003639364.

PMID
20377362
Full Text

Zagar, Timothy M., James R. Oleson, Zeljko Vujaskovic, Mark W. Dewhirst, Oana I. Craciunescu, Kimberly L. Blackwell, Leonard R. Prosnitz, and Ellen L. Jones. “Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data..” Int J Hyperthermia 26, no. 7 (2010): 612–17. https://doi.org/10.3109/02656736.2010.487194.

PMID
20849256
Full Text

Spector, Neil L., and Kimberly L. Blackwell. “Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer..” J Clin Oncol 27, no. 34 (December 1, 2009): 5838–47. https://doi.org/10.1200/JCO.2009.22.1507.

PMID
19884552
Full Text

Grunberg, S. M., J. Weeks, W. F. Magnan, J. Herndon, M. L. Naughton, K. L. Blackwell, M. E. Wood, et al. “Determination of utility scores for control of chemotherapy-induced nausea or vomiting - CALGB 309801.” Journal of Supportive Oncology 7, no. 5 (December 1, 2009).

Scholars@Duke

Westmoreland, Tammy J., Sajith M. Wickramasekara, Andrew Y. Guo, Alice L. Selim, Tiffany S. Winsor, Arno L. Greenleaf, Kimberly L. Blackwell, John A. Olson, Jeffrey R. Marks, and Craig B. Bennett. “Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae..” Plos One 4, no. 6 (June 8, 2009). https://doi.org/10.1371/journal.pone.0005830.

PMID
19503795
Full Text

Blackwell, K. L., M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, and H. J. Burstein. “Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens..” Ann Oncol 20, no. 6 (June 2009): 1026–31. https://doi.org/10.1093/annonc/mdn759.

PMID
19179558
Full Text

Kaufman, Bella, Maureen Trudeau, Ahmad Awada, Kimberly Blackwell, Thomas Bachelot, Vanessa Salazar, Michelle DeSilvio, et al. “Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study..” Lancet Oncol 10, no. 6 (June 2009): 581–88. https://doi.org/10.1016/S1470-2045(09)70087-7.

PMID
19394894
Full Text

Lacouture, M. E., S. M. Laabs, M. Koehler, R. W. Sweetman, A. J. Preston, A. Di Leo, H. L. Gomez, et al. “Analysis of dermatologic events in patients with cancer treated with lapatinib..” Breast Cancer Res Treat 114, no. 3 (April 2009): 485–93. https://doi.org/10.1007/s10549-008-0020-7.

PMID
18600445
Full Text

Hardee, Matthew E., Rose J. Eapen, Zahid N. Rabbani, Matthew R. Dreher, Jeffrey Marks, Kimberly L. Blackwell, and Mark W. Dewhirst. “Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors..” Cancer Chemother Pharmacol 63, no. 2 (January 2009): 219–28. https://doi.org/10.1007/s00280-008-0729-3.

PMID
18365198
Full Text

Pages